Inhibition of the mTOR pathway: A possible protective role in coronary artery disease

Annals of Medicine

Volumn 45, Issue 4, 2013, Pages 348-356

  Tarantino, Giovanni ^a   Capone, Domenico ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atherosclerosis; Mtor inhibitors; Mtor pathway

Indexed keywords

ADIPOCYTOKINE; ANTISENSE OLIGONUCLEOTIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHOLESTEROL; CYCLOSPORIN; EVEROLIMUS; FK 506 BINDING PROTEIN; GLUCOSE; GLYCOLYTIC ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; RIMONABANT; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TACROLIMUS;

ADIPOGENESIS; ADIPOSE TISSUE; ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOPHAGY; CARDIOMETABOLIC RISK; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CELL ENERGY; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENERGY BALANCE; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GRAFT SURVIVAL; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; KIDNEY TRANSPLANTATION; LIPID STORAGE; LIPOGENESIS; LIVER TRANSPLANTATION; MACROPHAGE FUNCTION; METABOLIC REGULATION; METABOLIC SYNDROME X; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIENT LIMITATION; OBESITY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN HOMEOSTASIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; UNFOLDED PROTEIN RESPONSE; WEIGHT GAIN; WHITE ADIPOSE TISSUE; WNT SIGNALING PATHWAY;

ADIPOSE TISSUE; ANIMALS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84878589100     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2013.770333     Document Type: Review

References (77)

1. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol. 2007; 22: 293-303.
2. Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, et al. Could infl ammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol. 2009; 21: 504-11.
3. Barbato A, Iacone R, Tarantino G, Russo O, Sorrentino P, Avallone S, et al.; Olivetti Heart Study Research Group. Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern Emerg Med. 2009; 4: 315-23.
4. Lee YS, Li P, Huh JY, Hwang IJ, Lu M, Kim JI, et al. Infl ammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes. 2011; 60: 2474-83.
5. Weston CR, Davis RJ. Th e JNK signal transduction pathway. Curr Opin Cell Biol. 2007; 19 : 142 -9.
6. Cho H, Black S C, Looper D, Shi M, Kelly-Sullivan D, Timofeevski S, et al. Pharmacological characterization of a small molecule inhibitor of c-Jun kinase. Am J Physiol Endocrinol Metab. 2008; 295: E1142-51.
7. Yu XX, Murray SF, Watts L, Booten SL, Tokorcheck J, Monia BP, et al. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice. Am J Physiol Endocrinol Metab. 2008; 295 : E436 -45.
8. Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. Biochim Biophys Acta. 2010; 1801: 327-37.
9. Hahn C, Orr AW, Sanders JM, Jhaveri KA, Schwartz MA. Th e subendothelial extracellular matrix modulates JNK activation by fl ow stress. Circ Res. 2009; 104: 995-1003.
10. Baker A R, Harte A L, Howell N, Pritlove D C, Ranasinghe A M, da Silva NF, et al. Epicardial adipose tissue as a source of nuclear factor-kappaB and c-Jun N-terminal kinase mediated infl ammation in patients with coronary artery disease. J Clin Endocrinol Metab. 2009 ; 94 : 261 -7.
11. Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol. 2008; 19: 295-300.
12. Tarantino G, Savastano S, Colao A, Capone D, Tarantino M, Grimaldi E, et al. Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease? World J Gastroenterol. 2011; 17: 5280-8.
13. Tsai J, Qiu W, Kohen-Avramoglu R, Adeli K. MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly. Arterioscler Th romb Vasc Biol. 2007; 27 : 211 -8.
14. Gubern A, Barceló -Torns M, Barneda D, L ó pez JM, Masgrau R, Picatoste F, et al. JNK and ceramide kinase govern the biogenesis of lipid droplets through activation of group IVA phospholipase A2. J Biol Chem. 2009; 284: 32359-69.
15. Nogueira TC, Graciano MF, Anh ê GF, Curi R, Bordin S, Carpinelli AR. Short-term modulation of extracellular signal-regulated kinase 1/2 and stress-activated protein kinase/c-Jun NH2-terminal kinase in pancreatic islets by glucose and palmitate: possible involvement of ceramide. Pancreas. 2009; 38: 585-92.
16. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124: 471-84.
17. Guertin DA, Sabatini DM. Defi ning the role of mTOR in cancer. Cancer Cell. 2007; 12 : 9 -22.
18. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/ PKB. Mol Cell. 2006; 22 : 159 -68.
19. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006; 5: 671-88.
20. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010; 22 : 169 -76.
21. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006; 94; 195-99.
22. Joungmok K, Mondira K, Benoit V, Kun-Liang. A MPK and mTOR regulate autophagy through direct phosphorylation of Ulk. Nature Cell Biology. 2011; 13: 132-41.
23. Qin L, Wang Z, Tao L, Wang Y. ER stress negatively regulates AKT/TSC/ mTOR pathway to enhance autophagy. Autophagy. 2010; 6: 239-47.
24. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001; 15 : 807 -26.
25. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005; 17 : 596 -603.
26. Jang BC, Paik JH, Kim SP, Shin DH, Song DK, Park JG, et al. Catalase induced expression of infl ammatory mediators via activation of NFkappaB, PI3K/AKT, p70S6K, and JNKs in BV2 microglia. Cell Signal. 2005; 17 : 625 -33.
27. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002; 8: 128-35.
28. Sandhofer A, Tatarczyk T, Kirchmair R, Iglseder B, Paulweber B, Patsch JR, et al. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. Atherosclerosis. 2009; 206: 265-9.
29. Belgore F M, Blann AD, Lip GY. Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fl uid samples: development and application of two new immunoassays. Clin Sci (Lond). 2001; 100 : 567 -75.
30. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000; 14 : 783 -94.
31. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenes. J Cell Biol. 2004; 167: 399-403.
32. Ginion A, Auquier J, Benton CR, Mouton C, Vanoverschelde JL, Hue L, et al. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake. Am J Physiol Heart Circ Physiol. 2011; 301: H469-77.
33. Cho HJ, Park J, Lee HW, Lee YS, Kim JB. Regulation of adipocyte diff erentiation and insulin action with rapamycin. Biochem Biophys Res Commun. 2004; 321 : 942 -8.
34. Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor- gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004; 53: 2748-56.
35. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology. 2005; 146: 1473-81.
36. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004; 431: 200-5.
37. Morice M C, Serrys P W, Sousa J E, Fajadet J, Ban Hayashi E, P erin M, et al.; RAVEL Study Group. Randomized Study with the Sirolimus- Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 ; 346 : 1773 -80.
38. Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Anti-atherosclerotic eff ects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2007; 292: H2721-8.
39. Schreml S, Lehle K, Birnbaum DE, Preuner JG. mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells. Int Immunopharmacol. 2007; 7 : 781 -90.
40. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, et al. Eff ects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002; 43 : 1170 -80.
41. Baetta R, Granata A, Canavesi M, Ferri N, Arnaboldi L, Bellosta S, et al. Everolimus inhibitors monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Th er. 2009; 328: 419-25.
42. Gou ë ffi c Y, P otter-Perigo S, C han C K, J ohnson P Y, B raun K, E vanko S P, et al. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. Atherosclerosis. 2007; 195: 23-30.
43. Waksman R, Pakala R, Burnett M S, Gulick C P, Leborgne L, Fournadjiev J, et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apo E knock-out mice. Cardiovasc Radiat Med. 2003; 4: 34-8.
44. Mueller MA, Beutner F, Teupser D, Ceglarek U, Th iery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR 2277;/ mice despite severe hypercholesterolemia. Atherosclerosis. 2008; 198: 39-48.
45. Chen WQ, Zhong L, Zhang L, Ji XP, Zhang M, Zhao YX, et al. Oral rapamycin attenuates infl ammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol. 2009; 156: 941-51.
46. Neal DAJ, Gimson AES, Gibbs P, Alexander AJM. Beneficial effects of converting liver transplant recipients from cyclosporin to tacrolimus on blood pressure, serum lipids and weight. Liver Transpl. 2001; 7: 533-9.
47. Wawrzynowicz-Syczewska M, Karpińska E, Jurczyk K, Laurans L, Boroń -Kaczmarska A. Risk factors and dynamics of weight gain in patients after liver transplantation. Ann Transplant. 2009; 14: 45-50.
48. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int. 2005; 18: 461-6.
49. Rovira J, Marcelo Arellano E, Burke JT, Brault Y, Moya-Rull D, Bañ ón-Maneus E, et al. Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int. 2008; 21 : 992 -8.
50. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006; 126 : 955 -68.
51. Vigneron F, Dos Santos P, Lemoine S, Bonnet M, Tariosse L, Couffinhal T, et al. GSK-3 α&χιρχ; at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc Res. 2011; 90 : 49 -56.
52. Alligier M, Meugnier E, Debard C, Lambert-Porcheron S, Chanseaume E, Sothier M, et al. Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans. J Clin Endocrinol Metab. 2012; 97: E183-92.
53. Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant. 2004; 18: 596-604.
54. Kramer NC, Peters TG, Rohr MS, Th acker LR, Vaughn WK. Benefi cial effect of cyclosporine on renal transplantation. A multicenter long-term study. Transplantation. 1990; 49: 343-8.
55. Am J Kidney Dis. 2004; 43: 943-52.
56. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000; 11 : 1735 -43.
57. Elmagd MM, Bakr MA, Metwally AH, Wahab AM. Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant. Exp Clin Transplant. 2008; 6: 42-7.
58. Tarantino G, Palmiero G, Polichetti G, Perfetti A, Sabbatini M, Basile V, et al. Long-term assessment of plasma lipids in transplant recipients treated with tacrolimus in relation to fatty liver. Int J Immunopathol Pharmacol. 2010; 23: 1303-8.
59. Augustine JJ, Hricik DE. Minimization of immunosuppression in kidney transplantation. Curr Opin Nephrol Hypertens. 2007; 16 : 535 -41.
60. Sharma NK, Das SK, Mondal AK, Hackney OG, Chu WS, Kern PA, et al. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J Clin Endocrinol Metab. 2008; 93: 4532-41.
61. Boden G, Duan X, Homko C, Molina EJ, Song W, Perez O, et al. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes. 2008; 57 : 2438 -44.
62. Vendrell J, Maym ó -Masip E, Tinahones F, Garc í a-Espa ñ a A, Megia A, Caubet E, et al. Tumor necrosis-like weak inducer of apoptosis as a proinfl ammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by infl ammation but not hypoxia. J Clin Endocrinol Metab. 2010; 95: 2983-92.
63. Gregor MF, Yang L, Fabbrini E, Mohammed BS, Eagon JC, Hotamisligil GS, et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes. 2009; 58: 693-700.
64. Alhusaini S, McGee K, Schisano B, Harte A, McTernan P, Kumar S, et al. Lipopolysaccharide, high glucose and saturated fatty acids induce endoplasmic reticulum stress in cultured primary human adipocytes: salicylate alleviates this stress. Biochem Biophys Res Commun. 2010; 397 : 472 -8.
65. Jiao P, Ma J, Feng B, Zhang H, Alan Diehl J, Eugene Chin Y, et al. FFA-induced adipocyte infl ammation and insulin resistance: involvement of ER stress and IKKb pathways. Obesity (Silver Spring). 2011; 19 : 483 -91.
66. Zhou QG, Zhou M, Hou FF, Peng X. Asymmetrical dimethylarginine triggers lipolysis and infl ammatory response via induction of endoplasmic reticulum stress in cultured adipocytes. Am J Physiol Endocrinol Metab. 2009; 296 : E869 -78.
67. Zhou L, Liu M, Zhang J, Chen H, Dong LQ, Liu F. DsbA-L alleviates endoplasmic reticulum stress-induced adiponectin downregulation. Diabetes. 2010; 59: 2809-16.
68. Xu L, Spinas GA, Niessen M. ER stress in adipocytes inhibits insulin signaling, represses lipolysis, and alters the secretion of adipokines without inhibiting glucose transport. Horm Metab Res. 2010; 42: 643-51.
69. Lefterova MI, Mullican SE, Tomaru T, Qatanani M, Schupp M, Lazar MA. Endoplasmic reticulum stress regulates adipocyte resistin expression. Diabetes. 2009; 58: 1879-86.
70. Ye R, Jung DY, Jun JY, Li J, Luo S, Ko HJ, et al. Grp78 heterozygosity promotes adaptive unfolded protein response and attenuates dietinduced obesity and insulin resistance. Diabetes. 2010; 59: 6-16.
71. da Luz G, Frederico MJ, da Silva S, Vitto MF, Cesconetto PA, de Pinho RA, et al. Endurance exercise training ameliorates insulin resistance and reticulum stress in adipose and hepatic tissue in obese rats. Eur J Appl Physiol. 2011; 111: 2015-23.
72. Cretenet G, Le Clech M, Gachon F. Circadian clock-coordinated 12 hr period rhythmic activation of the IRE1a pathway controls lipid metabolism in mouse liver. Cell Metab. 2010; 11: 47-57.
73. Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D. Dephosphorylation of translation initiation factor 2a enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab. 2008; 7; 520-32.
74. Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008; 134: 568-76.
75. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010; 11 : 467 -78.
76. Kammoun HL, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T, et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest. 2009 : 119; 1201 -15.
77. Boulb é s DR, Shaiken T, Sarbassov dos D. Endoplasmic reticulum is a main localization site of mTORC2. Biochem Biophys Res Commun. 2011; 413 : 46 -52.